Literature DB >> 24049183

Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Eddie A James1, Rebecca E LaFond, Theresa J Gates, Duy T Mai, Uma Malhotra, William W Kwok.   

Abstract

Yellow fever virus (YFV) can induce acute, life-threatening disease that is a significant health burden in areas where yellow fever is endemic, but it is preventable through vaccination. The live attenuated 17D YFV strain induces responses characterized by neutralizing antibodies and strong T cell responses. This vaccine provides an excellent model for studying human immunity. While several studies have characterized YFV-specific antibody and CD8(+) T cell responses, less is known about YFV-specific CD4(+) T cells. Here we characterize the epitope specificity, functional attributes, and dynamics of YFV-specific T cell responses in vaccinated subjects by investigating peripheral blood mononuclear cells by using HLA-DR tetramers. A total of 112 epitopes restricted by seven common HLA-DRB1 alleles were identified. Epitopes were present within all YFV proteins, but the capsid, envelope, NS2a, and NS3 proteins had the highest epitope density. Antibody blocking demonstrated that the majority of YFV-specific T cells were HLA-DR restricted. Therefore, CD4(+) T cell responses could be effectively characterized with HLA-DR tetramers. Ex vivo tetramer analysis revealed that YFV-specific T cells persisted at frequencies ranging from 0 to 100 cells per million that are detectable years after vaccination. Longitudinal analysis indicated that YFV-specific CD4(+) T cells reached peak frequencies, often exceeding 250 cells per million, approximately 2 weeks after vaccination. As frequencies subsequently declined, YFV-specific cells regained CCR7 expression, indicating a shift from effector to central memory. Cells were typically CXCR3 positive, suggesting Th1 polarization, and produced gamma interferon and other cytokines after reactivation in vitro. Therefore, YFV elicits robust early effector CD4(+) T cell responses that contract, forming a detectable memory population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24049183      PMCID: PMC3838168          DOI: 10.1128/JVI.01160-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

2.  Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay.

Authors:  A P Santos; D C S Matos; A L Bertho; S C F Mendonça; R Marcovistz
Journal:  Cytokine       Date:  2008-04-02       Impact factor: 3.861

3.  The early cellular signatures of protective immunity induced by live viral vaccination.

Authors:  Siegfried Kohler; Nicole Bethke; Matthias Böthe; Sophie Sommerick; Marco Frentsch; Chiara Romagnani; Matthias Niedrig; Andreas Thiel
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

4.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

5.  Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults.

Authors:  Maria Luiza Silva; Marina Angela Martins; Luçandra Ramos Espírito-Santo; Ana Carolina Campi-Azevedo; Denise Silveira-Lemos; José Geraldo Leite Ribeiro; Akira Homma; Erna Geessien Kroon; Andréa Teixeira-Carvalho; Silvana Maria Elói-Santos; Olindo Assis Martins-Filho
Journal:  Vaccine       Date:  2010-08-21       Impact factor: 3.641

6.  Direct ex vivo analysis of allergen-specific CD4+ T cells.

Authors:  William W Kwok; Michelle Roti; Jonathan H Delong; Venus Tan; Erik Wambre; Eddie A James; David Robinson
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

7.  Human immune memory to yellow fever and smallpox vaccination.

Authors:  Jens Wrammert; Joe Miller; Rama Akondy; Rafi Ahmed
Journal:  J Clin Immunol       Date:  2008-12-04       Impact factor: 8.317

8.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.

Authors:  Kim Blom; Monika Braun; Martin A Ivarsson; Veronica D Gonzalez; Karolin Falconer; Markus Moll; Hans-Gustaf Ljunggren; Jakob Michaëlsson; Johan K Sandberg
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more
  42 in total

1.  Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis.

Authors:  Samuel J Landry; Daniel L Moss; Da Cui; Ryan P Ferrie; Mitchell L Fullerton; Evan A Wells; Lu Yang; Nini Zhou; Thomas Dougherty; Ramgopal R Mettu
Journal:  Viral Immunol       Date:  2017-06-14       Impact factor: 2.257

2.  Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.

Authors:  Rama S Akondy; Philip L F Johnson; Helder I Nakaya; Srilatha Edupuganti; Mark J Mulligan; Benton Lawson; Joseph D Miller; Bali Pulendran; Rustom Antia; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

Review 3.  Transcriptomic immune profiles of human flavivirus-specific T-cell responses.

Authors:  Alba Grifoni; Yuan Tian; Alessandro Sette; Daniela Weiskopf
Journal:  Immunology       Date:  2020-01-07       Impact factor: 7.397

Review 4.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

Review 5.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

6.  Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction.

Authors:  Julia Schwaiger; Judith H Aberle; Karin Stiasny; Bernhard Knapp; Wolfgang Schreiner; Ingrid Fae; Gottfried Fischer; Ondrej Scheinost; Vaclav Chmelik; Franz X Heinz
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

7.  Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans.

Authors:  Lyndsey M Muehling; Duy T Mai; William W Kwok; Peter W Heymann; Anna Pomés; Judith A Woodfolk
Journal:  J Immunol       Date:  2016-09-02       Impact factor: 5.422

8.  Unsupervised capture and profiling of rare immune cells using multi-directional magnetic ratcheting.

Authors:  Coleman Murray; Hiromi Miwa; Manjima Dhar; Da Eun Park; Edward Pao; Jessica Martinez; Sireesha Kaanumale; Evelina Loghin; John Graf; Khadir Raddassi; William W Kwok; David Hafler; Chris Puleo; Dino Di Carlo
Journal:  Lab Chip       Date:  2018-08-07       Impact factor: 6.799

Review 9.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Authors:  Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy
Journal:  Expert Rev Vaccines       Date:  2019-02-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.